Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Malaria Journal|June 21, 2013
MMV in partnership: the Eurartesim® experienceDavid Ubben, Elizabeth M PollDiscovery Medicine|June 3, 2010
When is enough enough? The need for a robust pipeline of high-quality antimalarialsTimothy N Wells, Elizabeth M PollMalaria Journal|August 24, 2012
A framework for assessing the risk of resistance for anti-malarials in developmentXavier C Ding, David Ubben, Timothy N C WellsTravel Medicine and Infectious Disease|February 13, 2007
Medicines for Malaria Venture new developments in antimalarialsSolomon Nwaka, Lise Riopel, David Ubben, et al.Malaria Journal|April 13, 2013
Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in AfricaRicha S Chandra, John Orazem, David Ubben, et al.Reproductive Toxicology (Elmsford, N.Y.)|September 25, 2012
Piperaquine phosphate: reproduction studiesMonica Longo, Silvia Pace, Monica Messina, et al.Antimicrobial Agents and Chemotherapy|March 7, 2012
In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarialsFranco Borsini, William Crumb, Silvia Pace, et al.Malaria Journal|March 1, 2011
Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian childrenMichael Nambozi, Jean-Pierre Van Geertruyden, Sebastian Hachizovu, et al.Malaria Journal|January 26, 2010
Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?Bernhards Ogutu, Alfred B Tiono, Michael Makanga, et al.Clinical Drug Investigation|August 22, 2015
Effect of food on the pharmacokinetics of piperaquine and dihydroartemisininStephanie E Reuter, Allan M Evans, Sepehr Shakib, et al.Pageof 3